Bio-Rad Laboratories (BIO) Non Operating Investment Income (2018 - 2026)

Bio-Rad Laboratories (BIO) has reported Non Operating Investment Income for 9 consecutive years, with $458.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non Operating Investment Income rose 36.96% year-over-year to $458.0 million in Q2 2026; TTM through Jun 2026 was $254.0 million, a 39.1% increase from a year earlier, with the FY2025 full-year figure at $900.4 million, up 133.89% from the prior year.
• Non Operating Investment Income was $458.0 million for Q2 2026 at Bio-Rad Laboratories, up from -$738.2 million in the prior quarter.
• Over five years, Non Operating Investment Income peaked at $1.0 billion in Q4 2025 and troughed at -$4.5 billion in Q1 2022.
• A 5-year average of -$471.2 million and a median of $7.1 million in 2023 frame the typical range for Non Operating Investment Income.
• Across the five-year window, Non Operating Investment Income surged 8962.09% in 2022 and tumbled 2421.38% in 2026, its largest moves.
• Over 5 years, Non Operating Investment Income stood at $978.7 million in 2022, then plunged by 66.87% to $324.2 million in 2023, then slumped by 401.16% to -$976.5 million in 2024, then surged by 205.43% to $1.0 billion in 2025, then plunged by 55.51% to $458.0 million in 2026.
• The last three Non Operating Investment Income figures came in at $458.0 million (Q2 2026), -$738.2 million (Q1 2026), and $1.0 billion (Q4 2025), per Business Quant data.